A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Public ClinicalTrials.gov record NCT01866111. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, double-blind, randomized, placebo-controlled dose response study, with an 8-week prospective baseline and an 18 week double-blind treatment period (including a 6-week titration phase and 12 week maintenance phase), followed by a 3-week blinded study drug taper period (for subjects leaving the study) or a 2-week blinded conversion period (for subjects who will participate in the open-label extension). The primary objective of this study is to determine the effective dose range of YKP3089 as adjunctive therapy for the treatment of partial seizures. The trial will also evaluate the safety and tolerability of YKP3089 in the partial epilepsy population.
Study identification
- NCT ID
- NCT01866111
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 437 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 30, 2013
- Primary completion
- Apr 4, 2021
- Completion
- Oct 30, 2021
- Last update posted
- Jun 23, 2025
2013 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics | Phoenix | Arizona | 85013 | — |
| Clinical Trials, Inc. | Little Rock | Arkansas | 72205 | — |
| Kaiser Permanente, Department of Neurology | Anaheim | California | 92806 | — |
| Neuro-Pain Medical Center | Fresno | California | 93710 | — |
| West Los Angeles VA Medical Center, Clinical Research Center | Los Angeles | California | 90073 | — |
| Neuroresearch, Inc. - Torrance | Torrance | California | 90505 | — |
| Neuroresearch II, Inc. | Ventura | California | 93003 | — |
| Bradenton Research Center, Inc. | Bradenton | Florida | 34205 | — |
| Lovelace Scientific Resources, Inc. | Sarasota | Florida | 34233 | — |
| Consultants in Epilepsy & Neurology, PLLC | Boise | Idaho | 83702 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Mid-Atlantic Epilepsy and Sleep Center | Bethesda | Maryland | 20817 | — |
| Neurology Clinic PC | Waldorf | Maryland | 20603 | — |
| The Comprehensive Epilepsy Care Center for Children and Adults | St Louis | Missouri | 63017 | — |
| Northeast Regional Epilepsy Group | Hackensack | New Jersey | 07601 | — |
| NYU Comprehensive Epilepsy Center | New York | New York | 10016 | — |
| The Neurological Institute, PA | Charlotte | North Carolina | 28204 | — |
| Thomas Jefferson Comprehensive Epilepsy Center | Philadelphia | Pennsylvania | 19107 | — |
| Vanderbilt Epilepsy Clinic | Nashville | Tennessee | 37232 | — |
| Austin Epilepsy Care Center | Austin | Texas | 78758 | — |
| University of Virginia Comprehensive Epilepsy Program | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01866111, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2025 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01866111 live on ClinicalTrials.gov.